[Gene therapy and stem cell transplantation in PAD].
Therapeutic angiogenesis is a novel promising strategy that uses angiogenic factors and stem cell transplantation to increase blood perfusion in ischaemic lower limbs. In preliminary studies short term safety and feasibility of gene therapy by recombinant protein administration or gene transfer were proven. Early reports mostly fail to show an convincing efficacy. In the largest placebo-controlled study of therapeutic angiogenesis in severe PAD reported to date, the plasmid-based fibroblast growth factor was safe and significantly reduced amputation rates. The data suggest the efficacy of the angiogenic therapy and provide the basis for further larger trials to confirm these first results.
Lawall
H
H
Abteilung Angiologie/Diabetologie, SRH - Klinikum Karlsbad-Langensteinbach, Guttmann Str. 1, 76307 Karlsbad. Holger.Lawall@kkl.srh.de
D000671:Amputation, Surgical; D001157:Arterial Occlusive Diseases / Q000601:surgery / Q000628:therapy; D015316:Genetic Therapy; D006801:Humans; D016491:Peripheral Vascular Diseases / Q000601:surgery / Q000628:therapy*; D033581:Stem Cell Transplantation